Early-phase AACR 2026 data showed zoldonrasib producing objective responses in previously treated KRAS G12D–mutant non-small cell lung cancer (NSCLC), a population with no approved RAS-targeted options. Presented as part of an ongoing phase 1/1B program, the study reported confirmed objective response rate (ORR) of 52% in evaluable patients at the recommended phase 2 dose. The dataset included 40 patients evaluable for safety, with a median of two prior lines and high prior exposure to immune checkpoint inhibitors and platinum chemotherapy. Median follow-up was 13.1 months, and efficacy signals were reported in cohorts that had not received docetaxel. In addition to single-agent activity, investigators highlighted continued development plans including rational combinations—such as pairing with the multiselective RAS inhibitor daraxonrasib and exploring combination approaches with standard-of-care regimens. The early findings support further dose-escalation and phase 2 expansion efforts. Clinically, the reported disease control rate (DCR) of 93% and progression-free survival (PFS) of 11.1 months at the time of analysis add to mounting evidence that KRAS G12D is becoming druggable in settings beyond classic G12C targeting, though the data remain non-randomized and require confirmation later in development.